AstraZeneca Pharma India (506820) Q2 24/25 earnings summary

Executive summary

• Revenue from operations for Q2 FY25 was Rs 4,080 million, up from Rs 3,110.7 million in Q2 FY24, reflecting strong year-over-year growth.

• Profit after tax for Q2 FY25 was Rs 384.3 million, compared to Rs 523.7 million in Q2 FY24, impacted by exceptional items related to manufacturing site exit provisions.

• Total comprehensive income for the half-year ended 30 September 2024 was Rs 1,069.7 million, down from Rs 1,626.1 million in the prior year period.

Financial highlights

• Total income for Q2 FY25 was Rs 4,161.5 million, up from Rs 3,194.4 million in Q2 FY24.

• Earnings per share (basic and diluted) for the half-year ended 30 September 2024 was Rs 20.95, compared to Rs 42.49 in the prior year period.

• Cash and cash equivalents as of 30 September 2024 stood at Rs 4,965.2 million, slightly down from Rs 5,055.7 million as of 31 March 2024.

• Net cash generated from operating activities for H1 FY25 was Rs 384.5 million, compared to Rs 494.5 million in H1 FY24.

Outlook and guidance

• The company expects the exit from its manufacturing site to take more than 12 months, with ongoing efforts to find a buyer.